MannKind (MNKD) Affinity Trials Should be Low Risk, But Afrezza Approval Not Guaranteed - Analyst

Upcoming MannKind Corp. (Nasdaq: MNKD) Affinity Phase 1/2 trials should be a low risk event for investors.

Cowen's Simos Simeonidis commented today that there are fairly high chances of being positive, though the analyst is still cautious on Afrezza's chances of receiving FDA approval

MannKind would also need a commercial partner, but many potential pharmaceutical partners and investors are still skeptical about the need for inhaled insulin.

Cowen has MannKind at Market Perform and thinks the company is fully valued at $2.5 billion. Shares are down 1.9 percent early.

For an analyst ratings summary and ratings history on MannKind click here. For more ratings news on MannKind click here.

Shares of MannKind closed at $7.47 last Friday, with a 52 week range of $1.82-$8.33.

http://www.streetinsider.com/Analyst+Comments/MannKind+%28MNKD%29+Affinity+Trials+Should+be+Low+Risk%2C+But+Afrezza+Approval+Not+Guaranteed+-+Analyst/8590927.html